Table 2 Primary and secondary outcomes in both groups
Outcome | Vancomycin (n = 54) | Teicoplanin (n = 62) | p value |
|---|---|---|---|
Clinical failure | 14 (25.9%) | 38 (61.3%) | < 0.001 |
 Discontinuation due to treatment failure | 12 (22.2%) | 26 (41.9%) | 0.024 |
 Death | 2 (3.7%) | 12 (19.4%) | 0.010 |
Discontinuation due to side effects | 13 (24.1%) | 1 (1.6%) | < 0.001 |
Clinical cure | 27 (50.0%) | 23 (37.1%) | 0.162 |